The Colorectal Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Colorectal Cancer pipeline products will significantly revolutionize the Colorectal Cancer market dynamics.

DelveInsight’s “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Colorectal Cancer, historical and forecasted epidemiology as well as the Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Colorectal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Colorectal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Colorectal Cancer Market Insights

Some of the key facts of the Colorectal Cancer Market Report:

• The Colorectal Cancer market size was valued ~USD 13,000 million in 2023 and is anticipated to grow with a significant CAGR of 5% during the study period (2020-2034)

• In February 2025, Pfizer’s combination therapy for metastatic colorectal cancer (mCRC) achieved one of its main goals—enhancing progression-free survival (PFS)—in a Phase III clinical trial, reinforcing the potential for full regulatory approval. The BREAKWATER trial (NCT05217446), an open-label, active-controlled study, assessed a regimen combining Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab), and the chemotherapy mix mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin). The trial focused on treatment-naive mCRC patients with a BRAF V600E mutation.

• In February 2025, Averto Medical revealed that the FDA has awarded Breakthrough Device Designation to its ColoSeal™ Intraluminal Colonic Diversion (ICD) System. This innovative device is designed to enhance recovery and outcomes for colorectal surgery patients by potentially eliminating the requirement for a temporary ostomy.

• In January 2025, The FDA granted approval for Amgen’s KRAS G12C inhibitor, Lumakras, to be used in combination with Vectibix for the treatment of advanced colorectal cancer.

• In December 2024, EndoQuest Robotics gained FDA IDE approval for a clinical trial to evaluate its surgical robot in colorectal lesion removal. The trial will involve 50 participants across five US sites, focusing on the safety and performance of the system in ESD procedures (NCT06133387).

• In October 2024, U.S. regulators have prolonged their evaluation of Amgen’s LUMAKRAS (sotorasib) for second-line colorectal cancer (CRC) by three months, delaying a possible approval decision until January 17 of next year. This extension also temporarily reduces competitive pressure on Bristol Myers Squibb’s competing KRAS-inhibitor, KRAZATI (adagrasib).

• In June 2024, Bristol Myers Squibb announced US FDA accelerated approval of KRAZATI (adagrasib) in combination with cetuximab for adult patients with previously treated kras G12C-mutated locally advanced or metastatic colorectal cancer.

• In April 2024, ENHERTU was approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours, including colorectal cancer.

• Colorectal cancer is the third most frequently diagnosed cancer globally. In 2024, the United States is expected to report around 106,600 new cases of the disease. It remains the second leading cause of cancer-related deaths in the country for both men and women.

• In 2023, the United States represented approximately 30% of all newly diagnosed cases of colorectal cancer across the 7MM.

• In 2023, around 68,400 cases of colorectal cancer were reported in the United States among individuals aged 65-84 years.

• In 2023, approximately 52,000 cases of colorectal cancer were found in the right colon in the United States.

• The Surveillance, Epidemiology, and End Results (SEER) program published age and gender data for colorectal cancer patients. According to the registry, the distribution of cases by stage was as follows: 38% localized, 35% regional, 22% distant, and 4% unknown.

• Key Colorectal Cancer Companies: Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others

• Key Colorectal Cancer Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib), Niraparib, QL1706, Nivolumab, SGM-101, tucatinib, GRT-C901, Pembrolizumab, BXQ-350, Radspherin, MRTX849, Revumenib, Onvansertib, DKN-01, XL092, Atezolizumab, Nanrilkefusp alfa, pTTL, AK119, MRTX849,and others

• The Colorectal Cancer epidemiology based on gender analyzed that Colorectal Cancer is more common in men as compared to women

Colorectal Cancer Overview

Colorectal cancer is a type of cancer that begins in the colon or rectum, parts of the large intestine. It typically starts as small, non-cancerous growths called polyps, which can develop into cancer over time. The exact cause of colorectal cancer is unclear, but risk factors include age, family history, certain genetic conditions, and lifestyle factors like diet, smoking, and lack of physical activity. Symptoms may include changes in bowel habits, blood in stool, abdominal pain, and unexplained weight loss. Early detection through screening, such as colonoscopy, is key to improving outcomes, as treatment options like surgery, chemotherapy, and radiation can be effective when the cancer is caught early.

Get a Free sample for the Colorectal Cancer Market Report:

https://www.delveinsight.com/report-store/colorectal-cancer-crc-market

Colorectal Cancer Market

The dynamics of the Colorectal Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“According to the estimates, the highest market size of Colorectal Cancer was found in the United States, followed by Japan and the least was in Spain across the 7MM in 2021. Besides, the upcoming therapies of Colorectal Cancer are expected to combat the current unmet needs faced by the patients with Colorectal Cancer and add to the overall growth of the Colorectal Cancer market size.”

Colorectal Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Colorectal Cancer Epidemiology Segmentation:

The Colorectal Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Colorectal Cancer

• Prevalent Cases of Colorectal Cancer by severity

• Gender-specific Prevalence of Colorectal Cancer

• Diagnosed Cases of Episodic and Chronic Colorectal Cancer

Download the report to understand which factors are driving Colorectal Cancer epidemiology trends @ Colorectal Cancer Epidemiological Insights

Colorectal Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Colorectal Cancer market or expected to get launched during the study period. The analysis covers Colorectal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Colorectal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Colorectal Cancer Therapies and Key Companies

• FRUZAQLA (fruquintinib): Takeda

• TUKSYA (tucatinib): Genentech/Seagen

• ENHERTU (trastuzumab deruxtecan): AstraZeneca and Daiichi Sankyo

• Favezelimab + pembrolizumab: Merck

• LUMAKRAS (sotorasib): Amgen

• Niraparib: Ibrahim Halil Sahin

• QL1706: Qilu Pharmaceutical

• Nivolumab: Bristol-Myers Squibb

• SGM-101: Surgimab

• tucatinib: Seagen Inc.

• GRT-C901: Gritstone bio, Inc.

• Pembrolizumab: Merck Sharp & Dohme

• BXQ-350: Bexion Pharmaceuticals

• Radspherin: Oncoinvent AS

• MRTX849: Mirati Therapeutics

• Revumenib: Syndax Pharmaceuticals

• Onvansertib: Cardiff Oncology

• DKN-01: Leap Therapeutics, Inc.

• XL092: Exelixis

• Atezolizumab: AIO-Studien-gGmbH

• Nanrilkefusp alfa: SOTIO Biotech AG

• pTTL: Neogap Therapeutics AB

• AK119: Akeso

• MRTX849: Mirati Therapeutics Inc.

To know more about Colorectal Cancer treatment, visit @ Colorectal Cancer Medications

Colorectal Cancer Market Strengths

• Recent advances in pathological staging and identification of the mutational status of KRAS (exon2), BRAF (V600E), and PIK3CA have greatly helped in deciding a path for anti-EGFR therapy of mCRC patients

Colorectal Cancer Market Opportunities

• The recent inclination toward the development of mutation-specific mCRC therapies has led to the approvals of KEYTRUDA, OPDIVO with or without YERVOY and BRAFTOVI in combination with ERBITUX. This clearly, opens up a window for several upcoming mutation-targeted therapies to enter and capture the market

Scope of the Colorectal Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Colorectal Cancer Companies: Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others, and others

• Key Colorectal Cancer Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib), Niraparib, QL1706, Nivolumab, SGM-101, tucatinib, GRT-C901, Pembrolizumab, BXQ-350, Radspherin, MRTX849, Revumenib, Onvansertib, DKN-01, XL092, Atezolizumab, Nanrilkefusp alfa, pTTL, AK119, MRTX849, and others

• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies

• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Colorectal Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Colorectal Cancer market share @ Colorectal Cancer Treatment Landscape

Table of Contents

1. Colorectal Cancer Market Report Introduction

2. Executive Summary for Colorectal Cancer

3. SWOT analysis of Colorectal Cancer

4. Colorectal Cancer Patient Share (%) Overview at a Glance

5. Colorectal Cancer Market Overview at a Glance

6. Colorectal Cancer Disease Background and Overview

7. Colorectal Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Colorectal Cancer

9. Colorectal Cancer Current Treatment and Medical Practices

10. Colorectal Cancer Unmet Needs

11. Colorectal Cancer Emerging Therapies

12. Colorectal Cancer Market Outlook

13. Country-Wise Colorectal Cancer Market Analysis (2020–2034)

14. Colorectal Cancer Market Access and Reimbursement of Therapies

15. Colorectal Cancer Market Drivers

16. Colorectal Cancer Market Barriers

17. Colorectal Cancer Appendix

18. Colorectal Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/